International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 98,397 IPC common shares (ISIN: CA46016U1084) during the period of September 28 to October 2, 2026 under IPC’s previously announced normal course issuer bid / share repurchase program (NCIB).

IPC’s NCIB, announced on December 3, 2025, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and Commission Delegated Regulation (EU) No 2016/1052 (Safe Harbour Regulation) and the applicable rules and policies of the Toronto Stock Exchange (TSX) and Nasdaq Stockholm and applicable Canadian and Swedish securities laws.

During the period of September 28 to October 2, 2026, IPC repurchased a total of 78,397 IPC common shares on Nasdaq Stockholm. All of these share repurchases were carried out by Pareto Securities AB on behalf of IPC.

A summary and detailed breakdown of the transactions conducted on Nasdaq Stockholm during the period of September 28 to October 2, 2026 according to article 5.3 of MAR and article 2.3 of the Safe Harbour Regulation is available with this press release on IPC’s website: www.international-petroleum.com/news-and-media/press-releases.

During the same period, IPC purchased a total of 20,000 IPC common shares on the TSX. All of these share repurchases were carried out by ATB Securities Inc. on behalf of IPC.

All common shares repurchased by IPC under the NCIB will be cancelled. As at October 2, 2026, the total number of issued and outstanding IPC common shares is 111,727,666 with voting rights, of which IPC holds 98,397 common shares in treasury.

A total of 1,197,483 IPC common shares have been repurchased under the NCIB through the facilities of the TSX and Nasdaq Stockholm up to October 2, 2026. A maximum of 6,468,077 IPC common shares may be repurchased up to December 4, 2026, or until such earlier date as the NCIB is completed or terminated by IPC.

International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol “IPCO”.

For further information, please contact:

Rebecca Gordon
SVP Corporate Planning and Investor Relations
rebecca.gordon@international-petroleum.com
Tel: +41 22 595 10 50
Or Robert Eriksson
Media Manager
reriksson@rive6.ch
Tel: +46 701 11 26 15

 

This information was submitted for publication, through the contact persons set out above, at 10:30 CEST on October 5, 2026.

Forward-Looking Statements
This press release contains statements and information which constitute “forward-looking statements” or “forward-looking information” (within the meaning of applicable securities legislation). Such statements and information (together, “forward-looking statements”) relate to future events, including the Corporation’s future performance, business prospects or opportunities. Actual results may differ materially from those expressed or implied by forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Forward-looking statements speak only as of the date of this press release, unless otherwise indicated. IPC does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws.

All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, forecasts, guidance, budgets, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “forecast”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “budget” and similar expressions) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements with respect to: the intention and ability of IPC to acquire common shares under the NCIB, including the timing of any such purchases; the number of common shares to be cancelled and the timing of such cancellations; and the return of value to IPC’s shareholders as a result of any common share repurchases.

The forward-looking statements are based on certain key expectations and assumptions made by IPC, including expectations and assumptions concerning: the duration and impact of tariffs that are currently in effect on goods exported from or imported into Canada, and that other than the tariffs that are currently in effect, neither the U.S. nor Canada (i) increases the rate or scope of such tariffs, reenacts tariffs that are currently suspended, or imposes new tariffs, on the import of goods from one country to the other, including on oil and natural gas, and/or (ii) imposes any other form of tax, restriction or prohibition on the import or export of products from one country to the other, including on oil and natural gas; prevailing commodity prices and currency exchange rates; applicable royalty rates and tax laws; interest rates; future well production rates and reserve and contingent resource volumes; operating costs; IPC’s ability to maintain its existing credit ratings; IPC’s ability to achieve its performance targets; the timing of receipt of regulatory approvals; the performance of existing wells; the success obtained in drilling new wells; anticipated timing and results of capital expenditures; the sufficiency of budgeted capital expenditures in carrying out planned activities; the timing, location and extent of future drilling operations; the successful completion of acquisitions and dispositions and that IPC will be able to implement its standards, controls, procedures and policies in respect of any acquisitions and realize the expected synergies on the anticipated timeline or at all; the benefits of acquisitions; the state of the economy and the exploration and production business in the jurisdictions in which IPC operates and globally; the availability and cost of financing, labour and services; IPC’s intention to complete share repurchases under the normal course issuer bid program, including the funding of such share repurchases, existing and future market conditions, including with respect to the price of IPC’s common shares, and compliance with respect to applicable limitations under securities laws and regulations and stock exchange policies; and the ability to market crude oil, natural gas and natural gas liquids successfully.

Although IPC believes that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because IPC can give no assurances that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks.

These include, but are not limited to: general global economic, market and business conditions; the risks associated with the oil and gas industry in general such as operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of estimates and projections relating to reserves, resources, production, revenues, costs and expenses; health, safety and environmental risks; commodity price fluctuations; interest rate and exchange rate fluctuations; marketing and transportation; loss of markets; environmental and climate-related risks; competition; innovation and cybersecurity risks related to IPC’s systems, including costs of addressing or mitigating such risks; the ability to attract, engage and retain skilled employees; incorrect assessment of the value of acquisitions; failure to complete or realize the anticipated benefits of acquisitions or dispositions; the ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals; geopolitical conflicts, including current and potential future conflicts in Ukraine, the Middle East, South America and elsewhere, and their potential impact on, among other things, global market conditions; political or economic developments, including, without limitation, the risk that (i) the tariffs that are currently in effect on goods exported from or imported into Canada continue in effect for an extended period of time, the tariffs that have been threatened are implemented, that tariffs that are currently suspended are reactivated, the rate or scope of tariffs are increased, or new tariffs are imposed, including on oil and natural gas, (ii) the U.S. and/or Canada imposes any other form of tax, restriction or prohibition on the import or export of products from one country to the other, including on oil and natural gas, and (iii) the tariffs imposed or threatened to be imposed by the U.S. on other countries and retaliatory tariffs imposed or threatened to be imposed by other countries on the U.S. will trigger a broader global trade war which could have a material adverse effect on the Canadian, U.S. and global economies, and by extension the Canadian oil and natural gas industry and the Corporation, including by decreasing demand for, and the price of oil, and natural gas, disrupting supply chains, increasing costs, causing volatility in the global financial markets, and limiting access to financing; and changes in legislation, including but not limited to tax laws, royalties, environmental and abandonment regulations. Readers are cautioned that the foregoing list of factors is not exhaustive.

Additional information on these and other factors that could affect IPC, or its operations or financial results, are included in IPC’s annual information form for the year ended December 31, 2025 (See “Cautionary Statement Regarding Forward-Looking Information”, “Reserves and Resources Advisory” and “Risk Factors”), in the management’s discussion and analysis (MD&A) for the three and six months ended June 30, 2026 (See “Risk Factors”, “Cautionary Statement Regarding Forward-Looking Information” and “Reserves and Resources Advisory”) and other reports on file with applicable securities regulatory authorities, including previous financial reports, management’s discussion and analysis and material change reports, which may be accessed through the SEDAR+ website (www.sedarplus.ca) or IPC’s website (www.international-petroleum.com).

Attachment

  • Flyte Believes Its Proprietary Technology, Data, and Digital Booking Platform Can Disrupt the $11.6 Billion US Private Jet Charter Market
  • Company believes its newly built AI-technology stack can fundamentally transform the traditional charter model
  • Scalable Platform Connects Customers, Aircraft, Operators, and Aviation Services via VJET’s Expanding Integrated Network
  • Growth Strategy: Customer Acquisition, Network and Aircraft Fleet Expansion, and Building Brand Awareness to Drive Long-Term Shareholder Value
  • Flyte’s Value Proposition: Privacy, Comfort, Reliability, and Convenience – at a highly competitive price

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) —  Flyte Aviation, Inc. (NYSE American: VJET) (the “Company” or “Flyte”) today revealed its new corporate identity as it launches a historic new chapter in what it believes is a disruptive technology company.

Effective today, the Company changed its corporate name from Catheter Precision, Inc. to Flyte Aviation, Inc. and its NYSE American ticker symbol from “VTAK” to “VJET.” The changes highlight the Company’s growth trajectory as a leading private, regional jet aviation business.

The rebranding of the Company reflects a fundamental repositioning around aviation, technology, and the Flyte brand. Its strategy is to accelerate the growth of its proprietary, scalable, AI-driven platform designed to modernize how consumers discover, access, and book private aviation.

Commenting, David Jenkins, Executive Chairman and Chief Executive Officer of Flyte Aviation, said: “Today is a historic milestone for our company and the official launch of our AI tech-driven aviation platform anticipated to reshape how consumers access private aviation – all while building long-term value for our shareholders.”

Marc Sellouk, who founded Flyte in 2018, said, “Commercial air travel often leaves passengers facing last-minute schedule disruptions and cancellations as they are herded like sheep into tiny seats at seemingly ever-increasing fares amid reduced schedules. Conversely, private aviation is increasingly travelers’ go-to solution, especially for short-hop last minute flights, that can be booked rapidly on-demand.

“We analyzed and determined that within our fragmented industry, a primary challenge of travelers is the frustrating complexity they face when seeking to book private jets at competitive prices with ready availability,” Mr. Sellouk added. “We believe Flyte has addressed those challenges with its integrated suite of proprietary, AI-enabled technologies, and our laser focus on the customer experience. In the months ahead, we will be further upgrading and advancing our network to capture market share and widen our competitive moat.”

Disrupting a Fragmented, Rapidly Growing $11.6 billion Industry

Private aviation remains a highly fragmented industry, with aircraft owners, operators, and brokers serving customers across disconnected systems, legacy processes, and traditional sales channels. Flyte Aviation believes its newly built AI-technology stack can fundamentally transform that traditional model, much of whose legacy systems were built upon upgraded but fundamentally decades-old technologies.

According to a report by Fortune Business Insights, dated September 14, 2026, the U.S. private jet charter market represents an approximately $11.6 billion market in 2026 and, at an estimated 6.9% annual growth rate (CAGR), could exceed $14 billion by 2029 and $16 billion by 2031.

The Company has built a consumer-focused digital booking platform that combines technology, data, and an expanding aviation network to make discovering, pricing, and booking private aviation simpler, faster and more transparent. Flying in and out of quiet private airports — without the traffic jams surrounding commercial airports — with easy parking and ride-share access, is an ideal choice for travelers who value their time and comfort.

Flyte’s longer-term strategy is to build a robust technology platform capable of further disrupting its marketplace by connecting participants across the entire private North American aviation ecosystem.

Technology + Data + Network

Flyte is building an expanding digital network in which technology and data analytics play an important role across pricing, aircraft sourcing, customer acquisition, aircraft utilization, expanding geographical footprint, and the customer experience.

Each interaction with the Flyte platform strengthens the broader network by providing additional data-driven insights into customer demand, travel patterns, pricing, aircraft availability and market activity.

Near-Term Growth Catalysts

During the fourth quarter of 2026, which began October 1, Flyte plans to invest in an upgraded website, a mobile application, digital marketing, social media, public relations, AI data analytics, and customer acquisition, which the Company believes will provide customers with a significantly improved digital experience.

Exemplifying its brand building, last week Flyte announced it has established a partnership with the Hamptons International Film Festival (“HIFF”), in which Flyte has been named the ‘Official Air Travel Partner’ of the prestigious, 34th annual HIFF taking place October 2 through October 12, 2026. Flyte will have a prominent presence throughout the festival, which brings together leading filmmakers, actors, artists, executives, and audiences from around the world for screenings, conversations, and events across the East End.

Built to Scale

Listed on the NYSE American, Flyte believes its public-company structure, prominence, liquidity, and lower cost of capital provide important strategic competitive advantages within the private aviation industry.

The Company may utilize these advantages to pursue growth through a combination of organic expansion, strategic relationships, technology development, and acquisitions as it identifies high value-added opportunities. The strategy is not growth for growth’s sake; it is to deploy capital where it can generate the highest ROI with the goal of ultimately achieving per-share profitability and free cash flow.

Life Sciences update

It’s important for the company’s LockeT and VIVO customers to note that while the company is focusing its capital utilization to grow its private jet aviation business, its Life Sciences operations will not be capital constrained nor downsized. Current and prospective customers should not be concerned that any disruption to the operations of the Life Sciences subsidiary will occur. Furthermore, the Company is committed to continue to fund its multiple ongoing research trials and studies.

About Flyte Aviation

Flyte Aviation, Inc. (NYSE American: VJET) is a technology-enabled private aviation company focused on modernizing how consumers access private air travel. Through its Flyte brand, the Company operates a growing fleet of Cirrus Vision Jets and is building a scalable aviation platform designed to connect customers, aircraft, operators, and aviation services.

Flyte’s simple value proposition: privacy, comfort, reliability, and convenience – at a highly competitive price.

Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary, Ponderosa Air, LLC, Flyte is focused on delivering what it believes is a faster, safer and more convenient private aviation experience while expanding its technology, customer network, and geographic footprint. For more information, visit www.flyflyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company’s beliefs regarding its technology platform, competitive position and market opportunity, its planned fourth quarter 2026 investments, the Company’s future operations, business strategy, growth, technology platform, mobile application, customer acquisition, customer growth, network expansion, aircraft utilization, geographic expansion, strategic partnerships, acquisitions, access to capital, divestiture or monetization of medical-device assets, revenue growth, market share and long-term enterprise or shareholder value, are forward-looking statements.

Words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “seek,” “may,” “will,” “potential,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially include, among others: the limited operating history of the Company’s aviation business and the Company’s history of losses; the Company’s need for additional capital and the dilution that may result from future financings and from the conversion of its outstanding convertible preferred stock; the Company’s ability to develop, deploy and monetize its technology platform, including its AI-enabled features; competition, customer demand and general economic conditions; the availability of aircraft and pilots, fuel costs and safety-related events; the regulation of the Company’s operations by the Federal Aviation Administration and other governmental authorities; the Company’s ability to maintain compliance with the continued listing standards of the NYSE American; and risks relating to the Company’s Life Sciences business.

This press release also contains market and industry data, including estimates of the size and growth of the U.S. private jet charter market, derived from third-party sources. The Company has not independently verified such data, and such estimates involve assumptions and are subject to significant uncertainty.

Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of risks and uncertainties that could affect the Company’s business and future results. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

Investor Relations

(800) 763-0904
IR@flyflyte.com

ANNOUNCEMENT

A.P. Møller – Mærsk A/S – Transactions in connection with share buy-back program

On 5 February 2026, A.P. Møller – Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 6.3bn (around USD 1bn) to be executed over a period of 12 months. The second phase of the share buy-back program will run from 13 August 2026 up to 29 January 2027. The shares to be acquired will be limited to a total market value of DKK 3.15 billion (around USD 500m).

The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”)

The following transactions have been made under the program in the period 28 September to 2 October 2026:                        

  Number of A shares Average purchase price A shares, DKK Transaction value,
A shares, DKK
Accumulated, last announcement 46,698   781,826,240
28 September 2026 250 22,368.5600 5,592,140
29 September 2026 250 22,675.1200 5,668,780
30 September 2026 250 22,955.0400 5,738,760
1 October 2026 250 22,519.2800 5,629,820
2 October 2026 250 22,971.1200 5,742,780
Total 28-2 October Friday 1,250   28,372,280
Accumulated in the second phase of the program 9,700   207,844,150
Accumulated under the program 47,948   810,198,520
  Number of B shares Average purchase price B shares, DKK Transaction value,
B shares, DKK
Accumulated, last announcement (market and the Foundation) 186,792   3,203,183,822
28 September 2026 877 23,286.9783 20,422,680
29 September 2026 877 23,380.3535 20,504,570
30 September 2026 877 23,849.0194 20,915,590
1 October 2026 877 23,183.0559 20,331,540
2 October 2026 877 23,838.3352 20,906,220
Total 28-2 October Friday 4,385   103,080,600
Bought from the Foundation* 615 23,507.5485 14,457,142
Accumulated in the second phase of the program (market and the Foundation) 38,800   862,853,289
Accumulated under the program (market and the Foundation) 191,792   3,320,721,564

*) According to a separate agreement, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.

With the transactions stated above, the Company owns a total of 47,948 A shares and 251,378 B shares as treasury shares, corresponding to 2.04% of the share capital.                        
Details of each transaction are included as appendix.

Copenhagen, 5 October 2026

Contact persons:
Head of Investor Relations, Martin Dunwoodie, tel. +45 3363 3484
Head of Media Relations, Jesper Lov, tel. +45 6114 1521

Page 1 of 1

Attachments

To

Nasdaq Copenhagen A/S

  Executive Management
Bernstorffsgade 40
DK-1577 København V
www.rd.dk

Telephone +45 7012 5300

5 October 2026

Company Announcement 05.10.2026  

Prepayments, Realkredit Danmark A/S

Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as of Friday 2 October 2026. Please find the data in the attached file.

The information will also be available on www.rd.dk.

Yours sincerely

The Executive Management

Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068.

Attachment

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites

Further confirms resolution of FDA inspection-related matters at the Reykjavik site

REYKJAVIK, Iceland (October 5, 2026) – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company’s Reykjavik facility. This approval further confirms resolution of inspection-related matters at the Reykjavik site.

“This approval is important both operationally and as a further regulatory milestone for our Reykjavik facility,” said Lisa Graver, Chief Executive Officer of Alvotech. “The addition of DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial supply of AVT02 to the U.S. market. It also reflects the significant progress our teams have made in strengthening quality systems and manufacturing operations at the site.”

The second suite, DSM2, supports the complete drug substance manufacturing process, including cell culture and purification, and doubles Alvotech’s manufacturing capacity available to support U.S. supply. DSM2 is already approved for the manufacture of commercial drug substance for European markets, including for AVT02, AVT03, and AVT05. Following the FDA approval, Alvotech can now manufacture AVT02 drug substance for U.S. commercial supply in either DSM1 or DSM2, providing additional capacity and greater flexibility across its manufacturing operations.

The approval follows the FDA’s July 2026 closure of its most recent inspection of the Reykjavik facility with a Voluntary Action Indicated (VAI) classification. Alvotech therefore expects the FDA to be able to take action on other pending applications associated with the facility according to their respective goal dates. These include BLAs for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab), AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), AVT03, Alvotech’s proposed biosimilar to Prolia® and Xgeva® (denosumab) and AVT16/AVT80, Alvotech’s proposed biosimilars to Entyvio® (vedolizumab). Each application remains subject to the FDA’s individual review and regulatory decision.

About AVT02 / SIMLANDI® (adalimumab-ryvk)

AVT02 is a monoclonal antibody approved as a biosimilar to Humira® (adalimumab) in more than 50 countries globally, including the United States, Europe, Canada and Australia. It is currently marketed in the U.S. as SIMLANDI® and under private label, in Europe as HUKYNDRA®, in Canada as SIMLANDI® and in Australia as ADALACIP®. Teva Pharmaceuticals is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI® in the United States, while Alvotech is responsible for development and manufacturing. 

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Use of trademarks

Third party trademarks are the property of their respective owners.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Press Release

Atos secures £350 million application management contract with Metropolitan Police Service

Six-year contract with opportunity to extend for a further two years to deliver core services with the option of further services added at the discretion of the Authority

London, United Kingdom – October 5, 2026 – Atos, a global leader of AI-powered digital transformation, today announced the award of a six-year contract worth up to £350 million with the Metropolitan Police Service (MPS). Under the agreement, Atos will deliver service management, application management and application security services, with the option for the MPS to extend the scope to include managed cloud and digital workplace services.

The contract reinforces Atos’ long-standing relationship with the Metropolitan Police Service and its role as a trusted technology partner supporting one of the UK’s most critical public sector organisations.

Jamie Hewitt, director of Digital Product Delivery, Metropolitan Police Service, said:

“Our collaboration with Atos will provide a stable digital foundation for our officers and staff, supporting the ongoing modernisation and simplification of our application landscape and driving greater efficiency and effectiveness across the technology that underpins frontline policing.”

As part of the agreement, Atos will provide end-to-end service management and maintain key business applications across the MPS technology estate. The services will be delivered in line with ITIL best practices, ensuring high levels of availability, resilience and performance. IT Service Continuity Management will be central to the delivery model, helping to safeguard essential policing services, while robust security measures will protect data, systems and users across the estate.

Michael Herron, head of Atos UK&I, said:

“We are proud to expand our partnership with the Metropolitan Police Service, helping to support the critical digital infrastructure that underpins policing across London. This award reflects the expertise, resilience and dedication of our teams, as well as the trust we have built over many years of working together. We look forward to continuing to deliver secure, reliable and scalable services that support both frontline policing and the communities the MPS serves.”

In addition to the core services, the MPS has the option to expand the contract to include managed cloud services, providing greater end-to-end accountability for application performance and service delivery. The agreement also includes the potential for digital workplace services, enabling the management of end-user devices and secure access to the tools and platforms needed to support flexible and effective ways of working.

The partnership further supports Atos’ commitment to helping public sector organisations deliver secure, resilient and digitally enabled services that improve outcomes for citizens and communities.

***

About Atos 

Atos is the Atos Group brand dedicated to AI-powered, secure, end-to-end digital services. Atos designs, develops, and operates critical digital environments that drive performance, resilience and sovereignty, helping public and private organizations worldwide retain control over their data and infrastructures, while meeting regulatory requirements. 

With more than 54,000 employees serving over 4,500 clients across 54 countries, Atos helps modernize core IT systems, accelerate cloud and data transformation, strengthen cybersecurity, and deliver secure digital workplace environments to support its clients, its employees and society. Atos also provides consulting and advisory services through its Atos Amplify brand. 

A trusted partner in operating complex and mission-critical environments, Atos supports organizations across highly regulated and sovereign contexts. 

About Atos Group 

Atos Group is a global leader in digital transformation with c. 56,000 employees and annual revenue of c. €7.2 billion (at the go-forward perimeter), operating in 54 countries under two brands – Atos for services and Eviden for products and systems. European number one in cybersecurity and a leader in cloud, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos Group is listed on Euronext Paris.  

Press contact 

Tessa David | tessa.david@atos.ai | +44 (0)7947 755 911

Attachment

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites

Further confirms resolution of FDA inspection-related matters at the Reykjavik site

REYKJAVIK, Iceland, Oct. 05, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company’s Reykjavik facility. This approval further confirms resolution of inspection-related matters at the Reykjavik site.

“This approval is important both operationally and as a further regulatory milestone for our Reykjavik facility,” said Lisa Graver, Chief Executive Officer of Alvotech. “The addition of DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial supply of AVT02 to the U.S. market. It also reflects the significant progress our teams have made in strengthening quality systems and manufacturing operations at the site.”

The second suite, DSM2, supports the complete drug substance manufacturing process, including cell culture and purification, and doubles Alvotech’s manufacturing capacity available to support U.S. supply. DSM2 is already approved for the manufacture of commercial drug substance for European markets, including for AVT02, AVT03, and AVT05. Following the FDA approval, Alvotech can now manufacture AVT02 drug substance for U.S. commercial supply in either DSM1 or DSM2, providing additional capacity and greater flexibility across its manufacturing operations.

The approval follows the FDA’s July 2026 closure of its most recent inspection of the Reykjavik facility with a Voluntary Action Indicated (VAI) classification. Alvotech therefore expects the FDA to be able to take action on other pending applications associated with the facility according to their respective goal dates. These include BLAs for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab), AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), AVT03, Alvotech’s proposed biosimilar to Prolia® and Xgeva® (denosumab) and AVT16/AVT80, Alvotech’s proposed biosimilars to Entyvio® (vedolizumab). Each application remains subject to the FDA’s individual review and regulatory decision.

About AVT02 / SIMLANDI® (adalimumab-ryvk)

AVT02 is a monoclonal antibody approved as a biosimilar to Humira® (adalimumab) in more than 50 countries globally, including the United States, Europe, Canada and Australia. It is currently marketed in the U.S. as SIMLANDI® and under private label, in Europe as HUKYNDRA®, in Canada as SIMLANDI® and in Australia as ADALACIP®. Teva Pharmaceuticals is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI® in the United States, while Alvotech is responsible for development and manufacturing. 

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com

About Alvotech 

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Use of trademarks

Third party trademarks are the property of their respective owners.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

BEIJING, Oct. 05, 2026 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today provided its sales volume results for the third quarter of 2026.

  3Q 2026   3Q 2025   YTD 2026   YTD 2025
China Market 490,406   451,455   1,140,546   953,239
International Markets 47,051   14,418   93,222   66,037
Total 537,457   465,873   1,233,768   1,019,276

In the third quarter of 2026, NIU sold 537,457 units, including e-motorcycles, e-mopeds, e-bicycles, kick-scooters and e-bikes. Sales in the China and international markets were 490,406 and 47,051 units, respectively.

In China, sales volume increased by 9% year-over-year, with the N, M and F series continuing to rank among our best-selling product lines and catering to a diverse range of riding needs. During the quarter, NIU AIOS, which combines AI capabilities with human-centered interaction through customizable display features and natural voice control, received the Red Dot Winner distinction in the “Interface & User Experience Design” category of the Red Dot Award: Brands & Communication Design 2026. Looking ahead, we plan to further integrate advanced technologies across our product lineup to support a more personalized and connected riding experience.

In international markets, we continued to refine our product portfolio and tailor our market strategies to evolving local mobility needs, while advancing the long-term development of our international operations.

Our sales volume count disclosed above is based on the delivery from our manufacturing facility, which may vary slightly from the sales volume measured from a financial accounting and reporting point of view. NIU’s sales volume represents only one measure of the Company’s financial performance and should not be relied upon as an indicator of quarterly financial results, which depend on a variety of factors, including revenues from accessories, spare parts and services, cost of sales, operating expenses, etc.

About NIU

As the world’s leading provider of smart urban mobility solutions, NIU designs, manufactures and sells high-performance electric motorcycles, mopeds, bicycles, as well as kick-scooters and e-bikes. NIU has a diversified product portfolio that caters to the various demands of our users and addresses different urban travel scenarios. Currently, NIU offers two model lineups, comprising a number of different vehicle types. These include (i) the electric motorcycle, moped and bicycle series, including the NQi, MQi, UQi, FQi series and others, and (ii) the micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. NIU has adopted an omnichannel retail model, integrating the offline and online channels, to sell its products and provide services to users.

For more information, please visit www.niu.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as NIU’s strategic and operational plans, contain forward-looking statements. NIU may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NIU’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIU’s strategies; NIU’s future business development, financial condition and results of operations; NIU’s ability to maintain and enhance its “NIU” brand; its ability to innovate and successfully launch new products and services; its ability to maintain and expand its offline distribution network; its ability to satisfy the mandated safety standards relating to e-scooters; its ability to secure supply of components and raw materials used in e-scooters; its ability to manufacture, launch and sell smart e-scooters meeting customer expectations; its ability to grow collaboration with operation partners; its ability to control costs associated with its operations; general economic and business conditions in China and globally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIU’s filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and NIU does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

Niu Technologies
E-mail: ir@niu.com

Company announcement no. 49 2026 Danske Bank
Bernstorffsgade 40
DK-1577 København V
Tel. + 45 33 44 00 00

05 October 2026

Page 1 of 2

Danske Bank share buy-back programme: transactions in week 40

On 5 February 2026, Danske Bank A/S announced a share buy-back programme for a total of DKK 4.5 billion, with a maximum of 45,000,000 shares, in the period from 9 February 2026 to 29 January 2027, at the latest, as described in company announcement no. 6 2026.

The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions were made under the share buy-back programme in week 40:

  Number of shares VWAP DKK Gross value DKK
Accumulated, last announcement 8,095,131 338.1615 2,737,461,901
28 September 2026 14,269 381.4701 5,443,197
29 September 2026 14,368 379.4862 5,452,458
30 September 2026 22,311 377.3478 8,419,007
01 October 2026 300,423 365.7269 109,872,772
02 October 2026 300,595 364.1170 109,451,750
Total accumulated over week 40 651,966 366.0301 238,639,183
Total accumulated during the share buyback programme 8,747,097 340.2387 2,976,101,084

With the transactions stated above, the total accumulated number of own shares under the share buy-back programme corresponds to 1.072% of Danske Bank A/S’ share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.

Danske Bank

Contact: Claus Ingar Jensen, Head of Group Investor Relations, tel. +45 25 42 43 70

Nasdaq Copenhagen Number of shares VWAP DKK Gross value DKK
28 September 2026 8,746 381.3419 3,335,216
29 September 2026 9,163 379.5805 3,478,096
30 September 2026 14,268 377.1523 5,381,209
01 October 2026 207,070 365.4898 75,681,973
02 October 2026 205,948 364.2604 75,018,701
Total accumulated over week 40 445,195 365.8963 162,895,195
Total accumulated during the share buyback programme 5,562,412 340.3219 1,893,010,561

CBOE Europe Number of shares VWAP DKK Gross value DKK
28 September 2026 5,523 381.6730 2,107,980
29 September 2026 5,205 379.3201 1,974,361
30 September 2026 8,043 377.6945 3,037,797
01 October 2026 93,353 366.2529 34,190,807
02 October 2026 94,647 363.8049 34,433,042
Total accumulated over week 40 206,771 366.3182 75,743,987
Total accumulated during the share buyback programme 3,184,685 340.0934 1,083,090,505

Attachment

Head Office : 39, Esplanade du Général de Gaulle 92800 Puteaux La Défense, France  
Tel : + 33 (0) 1 59 23 65 00 – www.nexans.com  
a French Société Anonyme with a share capital of € 43,746,793 – R.C.S. Nanterre 393 525 852 – Id VAT FR 74 393 525 852  
                         
Disclosure of trading in own shares                    
From September 28 to October 2, 2026                  
Issuer : Nexans                      
Category : treasury shares                      
                         
Pursuant to applicable law on share buybacks, Nexans declares the following purchases of its own shares from September 28, 2026 to October 2, 2026  
                         
The trades have been executed within the framework of the description of the buyback program published on April 2nd, 2026, on the Company’s website (www.nexans.com) by an investment firm pursuant to a mandate.  
                         
Name of the Issuer Identity Code of the Issuer Day of the transaction Identity Code of Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code)            
NEXANS 96950015FU78G84UIV14 28/09/2026 FR0000044448 3 000 133.8779 XPAR            
NEXANS 96950015FU78G84UIV14 29/09/2026 FR0000044448 3 000 134.0492 XPAR            
NEXANS 96950015FU78G84UIV14 30/09/2026 FR0000044448 3 000 133.8887 XPAR            
NEXANS 96950015FU78G84UIV14 10/1/2026 FR0000044448 3 000 132.6020 XPAR            
NEXANS 96950015FU78G84UIV14 10/2/2026 FR0000044448 3 000 136.1946 XPAR            
      TOTAL 15,000                
                         
Name of the issuer Identity Code of the Issuer Name of the Broker Identity Code of the Broker Day/time of the transaction (Paris Time) Identity Code of the financial instrument Quantity bought Price per unit Currency Identity Code of the Market Reference number of the transaction Purpose of the buyback  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 09:05:38 FR0000044448 131 134.4000 EUR XPAR 3hBA62t9SZyUFcvx8SqSKgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 09:16:08 FR0000044448 1 133.5000 EUR XPAR sLiyp6khRK21fGfQpKT1AgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 09:21:28 FR0000044448 79 133.7000 EUR XPAR DE_GprwIQGaIkwPn0yjT2wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 09:34:49 FR0000044448 78 133.8000 EUR XPAR 9293LtJ5TaOvacWcLoy6LAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 09:38:05 FR0000044448 65 133.8000 EUR XPAR o0GjEAXxRUqq8Xcw5aFYPwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 09:38:05 FR0000044448 65 133.8000 EUR XPAR ryMY8oiVTBmChuT2bL6y-gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 09:38:05 FR0000044448 65 133.8000 EUR XPAR uK7Dpu46RB-zrS65wSO9LQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 09:59:31 FR0000044448 73 133.2000 EUR XPAR OmpDfaLjTFCpCL1DboNS3wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 10:24:44 FR0000044448 143 133.2000 EUR XPAR CKJ-4zNXTxC7jCasTndKfgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 11:01:39 FR0000044448 7 133.5000 EUR XPAR EY_PI__XTWCmpYWZ-3LnIwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 11:01:39 FR0000044448 66 133.5000 EUR XPAR ydxKEYjTQi-npBcl3GOnWQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 11:15:55 FR0000044448 69 133.0000 EUR XPAR wsTgygaTRmC45PS6N8hC8gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 11:31:49 FR0000044448 126 133.3000 EUR XPAR AgApyS4OR1Wvi_T8c5thuwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 12:03:37 FR0000044448 32 133.5000 EUR XPAR ci5UWqeyRO-DboD92yNUkQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 12:11:00 FR0000044448 52 133.4000 EUR XPAR 9dCbOwwURHuEqvmfq8iZNQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 12:11:00 FR0000044448 141 133.4000 EUR XPAR peSrulD5QuyiQ6dKScGy9wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 12:54:17 FR0000044448 82 134.2000 EUR XPAR Pt_xtePcTNmJXNVjd97qlgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 12:54:17 FR0000044448 70 134.2000 EUR XPAR pZYNIOM7TAmDYXxrWxkpowA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 13:16:27 FR0000044448 69 133.9000 EUR XPAR 1ecn7gWwQ6SXOJjgP6mCBAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 13:37:01 FR0000044448 2 134.0000 EUR XPAR yHKoc_-TSriO63pfXEsr4QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 13:37:01 FR0000044448 65 134.0000 EUR XPAR J-8i3MaNRcmS93T4gK_0tAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 14:04:13 FR0000044448 67 133.9000 EUR XPAR N7Bv88FlQPqFgYWJxf6r8wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 14:29:01 FR0000044448 70 133.8000 EUR XPAR UX73DDmNTquxBRU_QoXDvQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 14:29:01 FR0000044448 76 133.8000 EUR XPAR WXtSUe96T02cEId_XnTUTgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 15:01:20 FR0000044448 139 134.6000 EUR XPAR dWDVLou5RjmZl1W1LEMlJAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 15:22:34 FR0000044448 126 134.5000 EUR XPAR WTG7OMxGSMSBeqZb8xug1AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 15:30:07 FR0000044448 66 134.5000 EUR XPAR CYJmNP1_RriBYKLYRke2swA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 15:48:03 FR0000044448 15 134.6000 EUR XPAR DrQk7darQxO5pX7xTaISOgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 15:48:03 FR0000044448 53 134.6000 EUR XPAR YgJ7-t9cQ5yNA6-v1jK8ewA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 15:51:04 FR0000044448 18 134.7000 EUR XPAR 05DJHHWrQGCkAPlS3YFWyAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 15:51:04 FR0000044448 48 134.7000 EUR XPAR _U40pn9KTASd-pAz9RbEogA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 15:51:04 FR0000044448 12 134.7000 EUR XPAR a1xcKTa3QICq1ZRWK5-fogA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:00:04 FR0000044448 72 134.9000 EUR XPAR ZMNzKfnKTL2IL5EL0DXisgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:00:06 FR0000044448 73 134.8000 EUR XPAR fM8aDYK5S0qSx99igcByCgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:17:38 FR0000044448 66 134.6000 EUR XPAR RwuiwXzORi-2gp9b_XnXTAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:21:53 FR0000044448 72 134.7000 EUR XPAR 13P0RBzSRn-0Uw8foPLDGwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:32:44 FR0000044448 89 134.8000 EUR XPAR GgUQZ8SzQDiqo2xW2XBndQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:38:42 FR0000044448 77 134.1000 EUR XPAR BXmwMUiwSqiS2XwsHlnpfQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:44:03 FR0000044448 5 133.6000 EUR XPAR r8hb-9DNQ32cJ6fXuupiPwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:44:07 FR0000044448 63 133.6000 EUR XPAR yGP-JxYyTzmw5DnLmOWrdAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 16:44:11 FR0000044448 7 133.6000 EUR XPAR b9uUbfMlS3i7yOZVI-JkmgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 17:00:15 FR0000044448 158 132.9000 EUR XPAR 4f14L9IZRAOp1nL7sOqrLQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 17:15:45 FR0000044448 67 132.8000 EUR XPAR IFhGHjPBRzq6htXX32NOlwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 17:26:02 FR0000044448 6 132.6000 EUR XPAR 3467192362045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 17:26:02 FR0000044448 29 132.6000 EUR XPAR 3467192363045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 28/09/2026 17:26:15 FR0000044448 45 132.6000 EUR XPAR 3467192682045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 09:01:00 FR0000044448 18 135.1000 EUR XPAR BbGnNgjWQgaxo3pYA5XDJAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 09:01:25 FR0000044448 74 134.8000 EUR XPAR UeU8ipc-QLGs99RRysS9VAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 09:10:31 FR0000044448 70 134.6000 EUR XPAR Ij0aXLKUQo-rBoOYuZ69NwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 09:20:53 FR0000044448 67 133.5000 EUR XPAR jb7FcQ_URYaCgNj4dQSj6gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 09:27:33 FR0000044448 73 133.6000 EUR XPAR H5j-fBBmS9aXjYeqUINmwgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 09:37:17 FR0000044448 144 134.0000 EUR XPAR ZatBKajPQLydcER5MF6kqQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 09:43:29 FR0000044448 77 133.6000 EUR XPAR r5A-gcaTTBaN9SwMYf1-xQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 10:20:34 FR0000044448 74 133.0000 EUR XPAR kWIVUkxOSfGDH_oTJGdlIAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 10:20:34 FR0000044448 73 132.9000 EUR XPAR CEMlVnEYScOsD4K9XHm7YwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 10:30:49 FR0000044448 69 132.0000 EUR XPAR LDQJrqg8THC7tyyw3D_HBgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 11:09:24 FR0000044448 70 134.3000 EUR XPAR xOW62gd9Sg2Pfywtqjf41wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 11:15:21 FR0000044448 74 134.3000 EUR XPAR q43FvJYjQDSvrccPuyRyfQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 11:29:11 FR0000044448 78 134.0000 EUR XPAR ZTWmpbJWTW-fB8DjdY__igA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 11:29:11 FR0000044448 68 134.0000 EUR XPAR kkBcszvDQ8KHMediRKZzEgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 12:11:34 FR0000044448 74 133.8000 EUR XPAR KcrEu5QQQTOjrPEZQOPNDwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 12:30:34 FR0000044448 158 133.6000 EUR XPAR 4h135JaiQayBnLgEtktgUgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 13:04:02 FR0000044448 128 134.0000 EUR XPAR 0R8LoNRjSYKrw60yt3EkMwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 14:03:36 FR0000044448 183 134.6000 EUR XPAR Jxv-7ERvRHaxFmOiDLtlYQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 14:46:04 FR0000044448 67 134.4000 EUR XPAR AObnU-XqTCO460YiJLWewQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 14:51:17 FR0000044448 168 134.2000 EUR XPAR HFpFlNK1TQC8uyOHP0CaPQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 15:20:57 FR0000044448 147 134.0000 EUR XPAR pug6J9arRLmn5CnTosoAxwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 15:30:01 FR0000044448 71 133.6000 EUR XPAR j_h5qJ_9SsOdHC4JTkXJXgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 15:44:21 FR0000044448 78 134.0000 EUR XPAR T-hkIr0_Q2mCNVTWFtoDNAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 15:49:38 FR0000044448 66 134.5000 EUR XPAR iQcCVr4BSOye6xOcSbcMCQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 15:57:16 FR0000044448 72 134.6000 EUR XPAR VR-cHiRLQeKkest59XQVggA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 15:57:16 FR0000044448 69 134.6000 EUR XPAR g1FJj5joSUONuG0cEqqTFAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 16:11:50 FR0000044448 66 134.4000 EUR XPAR GNMoU55ISbeH1AaoJ_Wq1AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 16:24:07 FR0000044448 66 134.8000 EUR XPAR O0XMpG1hTlC0W3Ii4AKXTgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 16:28:56 FR0000044448 74 134.6000 EUR XPAR 0pfmDNR2Rga-51cT1pLDsAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 16:41:54 FR0000044448 77 134.4000 EUR XPAR idqF2kDpTUK2kLvVwLC9QQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 16:41:58 FR0000044448 72 134.3000 EUR XPAR b1WkZiRbTEyGJMov7eMKWwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 17:02:21 FR0000044448 67 134.3000 EUR XPAR _XRHuw5mQbOKREcmVMerhQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 17:04:38 FR0000044448 34 134.2000 EUR XPAR d2Slm1cOSr2BKWjHTTOICAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 17:04:38 FR0000044448 32 134.2000 EUR XPAR X5qUW92WSleXCVi8mwFLogA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 17:06:14 FR0000044448 65 134.1000 EUR XPAR nyGxpL-ZSyKbK-FwJlOYMQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 17:14:31 FR0000044448 65 133.9000 EUR XPAR cap5M73iR3ugaZaila4-RwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 29/09/2026 17:26:53 FR0000044448 72 133.7000 EUR XPAR 3468476732045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 09:04:43 FR0000044448 147 134.5000 EUR XPAR _RrYgRQuSGqUsLjvwjDX6AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 09:14:10 FR0000044448 68 134.7000 EUR XPAR 83ONgZC9TLimA6DRMsH8MQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 09:25:15 FR0000044448 76 134.4000 EUR XPAR OKzk_nYJSJSEXvC_B9MKBAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 09:31:37 FR0000044448 79 134.1000 EUR XPAR FsbxTr_ISJW4kGMPA3OSGQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 09:37:16 FR0000044448 67 134.3000 EUR XPAR GtZO6PNrQVmI5HDb94Ho5QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 09:47:13 FR0000044448 133 134.5000 EUR XPAR obonWqfAQeKQq8h0jZudBgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 10:06:52 FR0000044448 128 134.4000 EUR XPAR 9oS34ixGQ1a6J4K3PlsYfgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 10:18:31 FR0000044448 134 134.0000 EUR XPAR EUVd-hrYR6SKzznT5MaM3QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 10:27:14 FR0000044448 5 134.0000 EUR XPAR Edg-VRfPQLS0MN1ByAIebQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 10:27:14 FR0000044448 60 134.0000 EUR XPAR swja4KTlQpqWJin__2cQwgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 10:54:27 FR0000044448 164 133.8000 EUR XPAR 0-k2FoGEQtmCNBaEZHWV5gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 11:10:51 FR0000044448 86 133.7000 EUR XPAR _X-yE9fRTBWAmw5wB1_FKAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 11:23:02 FR0000044448 71 133.6000 EUR XPAR GYMWLhXoSt-yN_zh4yI6ugA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 11:43:24 FR0000044448 52 133.4000 EUR XPAR uWL6onpER-mmOJ16cRuHKgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 11:43:24 FR0000044448 14 133.4000 EUR XPAR 6OwnhzVIRryk2UTFXfLPBAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:18:27 FR0000044448 40 134.3000 EUR XPAR AVhG2UUKTOaRTVs4BAd_CgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:18:27 FR0000044448 33 134.3000 EUR XPAR MvRPEV8QRBqPUcl3R9ZyNQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:18:27 FR0000044448 2 134.3000 EUR XPAR b1ou-hf-To-bUhl6HalfrQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:23:36 FR0000044448 62 134.2000 EUR XPAR pO53vvS7Q6WmEFFqyOUe1wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:23:36 FR0000044448 44 134.2000 EUR XPAR 21vPmQrHRmuFK_CcOXsJ0wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:23:36 FR0000044448 18 134.2000 EUR XPAR vheBVVujTJeZ19ARs4mTIgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:23:36 FR0000044448 38 134.2000 EUR XPAR wHD3b_DhQVuicD7-Ypo45QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:24:10 FR0000044448 2 134.1000 EUR XPAR oV0dOn4qTZidlEPkz3DeBQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 12:44:49 FR0000044448 66 134.3000 EUR XPAR 0gAKEWCTTc6c03nhaw_DAQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 13:07:34 FR0000044448 72 134.1000 EUR XPAR 7xh1hNSNT2W9R4SedBRMEwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 13:27:01 FR0000044448 67 134.4000 EUR XPAR IB8425lKTgmrmzBllYe59QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 13:35:04 FR0000044448 83 134.4000 EUR XPAR mZbhDKH9TwG2gxxuIGoMpwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 13:53:04 FR0000044448 74 134.2000 EUR XPAR LlG7_1tTSdKEDxceRdPPbgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 14:15:21 FR0000044448 68 134.0000 EUR XPAR 9wmTac3tSxW1LhY1pDsVowA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 14:57:41 FR0000044448 83 135.1000 EUR XPAR WWAHVzTuToGLS7VWEgZRlQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 15:09:07 FR0000044448 138 135.0000 EUR XPAR ZF9K-_mFSKet6ppfa8xTzQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 15:27:57 FR0000044448 66 134.1000 EUR XPAR cAPt5I0NTguJzOd_J-bT0gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 15:43:59 FR0000044448 72 133.3000 EUR XPAR 4zJX50BGRzSYNxzCIWt6OgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 15:48:04 FR0000044448 4 132.9000 EUR XPAR TzibaTJATI2_tsPisqHaQAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 15:48:05 FR0000044448 63 132.9000 EUR XPAR pddDc5aIQPG5xBrMbxmmBQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 16:00:12 FR0000044448 77 133.6000 EUR XPAR mUtnLkMIRWSI9MdGikgyMgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 16:00:12 FR0000044448 78 133.6000 EUR XPAR rkFbgzb2QO2UwWmnde6c-AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 16:32:47 FR0000044448 59 132.5000 EUR XPAR XbwwtjGwT6C3dU5KolCfjwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 16:32:47 FR0000044448 22 132.5000 EUR XPAR psLI_WQaTPuqvA_wfGn8jAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 16:47:23 FR0000044448 63 132.6000 EUR XPAR 5uxtj78IQciSc_IqB_6JoQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 16:47:24 FR0000044448 3 132.6000 EUR XPAR Vw0i93_hSXmwbzvk1UQNgQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 16:52:30 FR0000044448 47 132.6000 EUR XPAR 4vloIL9ZTlW6D55_5gG0JAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 16:52:33 FR0000044448 19 132.6000 EUR XPAR hKwixpN6Rz-kns6kUgBYQgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 17:00:30 FR0000044448 48 132.4000 EUR XPAR vb_bW6prSTW-HpdjuPr2iQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 17:00:30 FR0000044448 49 132.4000 EUR XPAR _N4KQKOwQ1u1rJ20lhfOlwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 17:00:30 FR0000044448 41 132.4000 EUR XPAR CmzMI3BpQeyFIz1vWmgtQgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 30/09/2026 17:24:45 FR0000044448 115 132.4000 EUR XPAR n1o-NG1cT2eMcE__f-YDGQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 09:06:29 FR0000044448 154 134.0000 EUR XPAR MgSnfo7nTIClqQXiU-nx9gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 09:21:30 FR0000044448 72 132.7000 EUR XPAR SrBk_pNeSwiucdLAePMr2AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 09:30:00 FR0000044448 77 132.1000 EUR XPAR KwGhZk_hQj-adKWttMC7uAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 09:44:38 FR0000044448 67 132.9000 EUR XPAR YGqtXrYNTa25dVtX0zayqQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 09:57:00 FR0000044448 66 133.2000 EUR XPAR 2oCKXTSOQQ-EKN18BcLuGwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 10:06:25 FR0000044448 65 132.3000 EUR XPAR 6pa0eIT3TY6Oq9u2gdZzQwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 10:17:18 FR0000044448 12 132.0000 EUR XPAR 6xsmEhU_RBa7bR_KC4M37gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 10:17:18 FR0000044448 12 132.0000 EUR XPAR HuNklYQoTvGqNZsMqHXNVwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 10:26:48 FR0000044448 80 132.5000 EUR XPAR LvICDaMcT8O8L44-RZcEyAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 10:42:24 FR0000044448 79 132.8000 EUR XPAR 2oI78MjaSsaSVfeaUpb_6gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 10:52:55 FR0000044448 72 132.6000 EUR XPAR w0l62POnTcGWetLFcYICzAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 11:16:20 FR0000044448 29 132.8000 EUR XPAR -QLVeOHGQki0dlE4XaEMrQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 11:16:20 FR0000044448 4 132.8000 EUR XPAR A7rhPLakQPGg4wXIOLIpDQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 11:16:20 FR0000044448 13 132.8000 EUR XPAR VQoKQOr2REONv4oV7bHn9wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 11:18:24 FR0000044448 180 132.7000 EUR XPAR A_I04XUTQUWzJolvsW8gygA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 11:58:22 FR0000044448 1 132.6000 EUR XPAR A1YXsKVFTXOAm9qTLBVcBAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 12:00:04 FR0000044448 163 132.5000 EUR XPAR cySa9YkNQrOwmrWaiVUbqQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 12:48:06 FR0000044448 97 132.7000 EUR XPAR MngKg4dBSzKTuy4I3uJJbgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 13:07:04 FR0000044448 137 132.1000 EUR XPAR jKIK_DXJQdmbPNDNZ0Jz-wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 13:52:00 FR0000044448 130 131.9000 EUR XPAR o98B92oETLeTckCl5fLi6QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 14:26:04 FR0000044448 141 131.8000 EUR XPAR GyDLQEWNScOFskMsaKcMEgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 14:26:04 FR0000044448 36 131.8000 EUR XPAR sE6bBU9AS5WarDRZOFR7uwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 15:03:00 FR0000044448 17 132.1000 EUR XPAR AnrKIc6USeSa2s4ERSiVOwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 15:03:00 FR0000044448 54 132.1000 EUR XPAR FvkvDgwkT7a5jjf1ad-MgAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 15:13:06 FR0000044448 70 132.1000 EUR XPAR PIHVAidlTPiug0KMZYIdCQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 15:21:23 FR0000044448 70 132.2000 EUR XPAR ZILI6L9PTsGBe_ROXvb5rQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 15:31:30 FR0000044448 66 132.2000 EUR XPAR pIW8GAQYRMK6TGKcDKaEVwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 15:31:30 FR0000044448 83 132.2000 EUR XPAR aLvzvVdhTQ6Afz8VrJ0WJwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 15:43:15 FR0000044448 71 131.9000 EUR XPAR f28gsT5-Tamzc6aOcwxCCQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 15:55:20 FR0000044448 90 132.6000 EUR XPAR XavhP7EVQ8eYcIzGXKgYgwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 16:05:01 FR0000044448 30 132.1000 EUR XPAR 0-Z3I6IrTA2CWEfm9hB0OQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 16:05:01 FR0000044448 36 132.1000 EUR XPAR 6cHDFiPBRWyQpCI4MKB92AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 16:11:51 FR0000044448 77 132.2000 EUR XPAR 9KjGsq_pQjCtrxZQ-g6EIgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 16:21:32 FR0000044448 94 133.1000 EUR XPAR res9SGv5ThaakwFbp2eWBQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 16:31:01 FR0000044448 67 133.1000 EUR XPAR Z_Lo4RtVSiuIfvLMyXrBoAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 16:40:26 FR0000044448 75 133.7000 EUR XPAR DkFngce2SCaEQopL248LtQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 16:50:49 FR0000044448 72 133.0000 EUR XPAR 1taUrb4LQnCr57sBZuLg1gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 16:58:25 FR0000044448 71 133.0000 EUR XPAR vxMiKm3mSpaBbSfaGO7B8AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 17:03:07 FR0000044448 81 132.8000 EUR XPAR HI6gLP-1R1-B7qXytHBXGgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 17:03:07 FR0000044448 79 132.8000 EUR XPAR VzxgWouCSKqfpAPA6mVBfgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 17:24:37 FR0000044448 11 133.4000 EUR XPAR 3471140933045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 01/10/2026 17:26:02 FR0000044448 99 133.4000 EUR XPAR 3471144488045 MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 09:01:07 FR0000044448 75 134.3000 EUR XPAR 43UTFUVzQ6CfXVOuJJlw0wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 09:15:00 FR0000044448 66 135.4000 EUR XPAR T8b-HP6zSQGDckvBBpAMjwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 09:15:59 FR0000044448 75 134.8000 EUR XPAR 1fzqHTCeRlegq27gI6kLogA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 09:30:36 FR0000044448 78 134.0000 EUR XPAR CeWoIJfERxqKWC_779jZawA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 09:45:02 FR0000044448 68 134.4000 EUR XPAR i_S0MMReRnKvuRfLPCI_2gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 09:57:31 FR0000044448 73 135.8000 EUR XPAR F8071d72SUiViIVOEJmuLwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 10:10:08 FR0000044448 84 136.8000 EUR XPAR HE0Vg4orSLaTKels3Md7WgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 10:27:05 FR0000044448 68 136.1000 EUR XPAR pLqqGqSeQq-n6-G1G04fAwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 10:33:14 FR0000044448 69 136.0000 EUR XPAR 8mTv2t2hSO2lO4DKSEpjngA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 10:49:41 FR0000044448 84 136.4000 EUR XPAR J6_bU8pGRue7BUdtL6yZjgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 11:11:06 FR0000044448 2 136.4000 EUR XPAR d50T3jY8Rsql5YqqaAC_NgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 11:12:57 FR0000044448 206 136.6000 EUR XPAR moCQxej7ReinfVtIL8d-sQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 11:46:47 FR0000044448 170 136.1000 EUR XPAR ZqUO0mWzRm23KsoVVlD5-AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 12:26:29 FR0000044448 120 135.5000 EUR XPAR 2UkE2igBRpyhTW7nMVuedQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 12:46:08 FR0000044448 68 136.0000 EUR XPAR -yTtaDL_Q4GRZMxfzNmZsAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 13:08:08 FR0000044448 67 136.3000 EUR XPAR DANHra5KRpSblCXCTmG57wA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 14:00:11 FR0000044448 48 135.5000 EUR XPAR _lE2Hme9RiuXPKLOX_HexQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 14:09:40 FR0000044448 102 135.5000 EUR XPAR l7pPti7ZRe6cRyDZojny0QA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 14:29:03 FR0000044448 159 135.3000 EUR XPAR TH7XvbFtRX-SkxrUNqKuzgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 14:55:22 FR0000044448 69 136.2000 EUR XPAR BVbm3Ec7RK-IyeenFZeuzgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 14:55:22 FR0000044448 66 136.2000 EUR XPAR s-rpKQX4QXeHJS8tMbPvkwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 15:22:58 FR0000044448 3 136.0000 EUR XPAR rkuCrFPcTrWbEl9oPqdAwwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 15:22:58 FR0000044448 102 136.0000 EUR XPAR AYZaE4CFT-m5-npByj0k3AA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 15:22:58 FR0000044448 49 136.0000 EUR XPAR zm778D7pQJSqNdiD6nu6rwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 15:40:23 FR0000044448 68 136.8000 EUR XPAR osF-LEjjRHGLezlcmFl9dQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 15:47:02 FR0000044448 78 137.5000 EUR XPAR OKySiZV-S1W0JAJ6f_xRjwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 15:54:45 FR0000044448 108 136.5000 EUR XPAR 7VbgysLGTyupXvN34rdvcQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:06:59 FR0000044448 79 137.0000 EUR XPAR DlhsnqAdT46_nWU3Se6-LAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:13:27 FR0000044448 88 137.1000 EUR XPAR LMlrhRgbQ5yXTDGu9qsGlQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:26:07 FR0000044448 5 137.0000 EUR XPAR zaEMmJO7T1SGITujXguzOAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:26:07 FR0000044448 71 137.0000 EUR XPAR CArEaFnrSFagKUgnXkK9vgA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:26:07 FR0000044448 28 137.0000 EUR XPAR _-ajJ_QsRSe63b4TqvdBbQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:41:59 FR0000044448 28 137.3000 EUR XPAR opVrax4SQd2F3M7Lft3zqAA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:41:59 FR0000044448 52 137.3000 EUR XPAR SQl0x4hjTR2pLQTOc4ByfQA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:46:37 FR0000044448 72 137.1000 EUR XPAR vkU7cW7NSyKCbylACO539gA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 16:57:21 FR0000044448 117 137.5000 EUR XPAR 1hY4XKZISweLhmWYGsinzwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 17:07:37 FR0000044448 140 137.0000 EUR XPAR X1a0CWMzTNW4cpekfoKMfwA MAR Art.5 §2c)  
NEXANS 96950015FU78G84UIV14 Natixis KX1WK48MPD4Y2NCUIZ63 02/10/2026 17:16:26 FR0000044448 95 136.7000 EUR XPAR 3472251088045 MAR Art.5 §2c)  
                         
                         
Verification  
  Quantité PMP
  0 #DIV/0!
  #REF! #REF!
  #REF! #DIV/0!

 

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.